AD is mainly a Th2-driven disease, characterized by expression of IL-4, IL-5 and IL-13, and the levels of these cytokines can also predict the outcomes of anti-IL-4, anti-IL-5 and anti-IL-13 biologics therapies (Bakker et al., 2020). The gene discussed is IL13; the disease is Alzheimer disease.